AA is a chronic, immune-mediated dermatologic condition characterized by non-scarring hair loss, affecting approximately 1% to 2% of the global population. Its unpredictable course and visible ...

Q: At about 26 years old, my father became sick and lost all of his hair. Not only did he lose hair on his head, he had no eyebrows, eyelashes or beard and even lost the hair on his arms and legs. Do ...

Dear Doctors: At about 26 years old, my father became sick and lost all of his hair. Not only did he lose hair on his head, he had no eyebrows, eyelashes or beard and even lost the hair on his arms ...

Dear Doctors: At about 26 years old, my father became sick and lost all of his hair. Not only did he lose hair on his head, he had no eyebrows, eyelashes or beard and even lost the hair on his arms ...

Baricitinib was generally well-tolerated. Acne was the most common adverse event (17.6%), followed by dyslipidemia (7.8%). Asthenia, elevated liver enzymes, and weight gain each occurred in fewer than ...

5 Things to Avoid When You Have Alopecia Areata Alopecia areata is an autoimmune disease in which the body attacks the hair follicles. If you’re one of the 6.8 million people in the U.S. with this ...

We all shed some hair every day—around 100 strands, which is totally normal. But let us be real, managing your hair can sometimes feel like a full-time job. From styling to preventing damage, it is ...

Patients with alopecia areata are at a greater risk for psychiatric disorders than control patients, including depression and anxiety, among others.

For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for the hair-loss disease alopecia areata (AA). The second replicate ...

The authors found that after 9 months of baricitinib treatment, the patient had reduced alopecic patches, increased hair density, and resolved inflammation.” — Melissa Zundell, BS NEW YORK, NY, UNITED ...

Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...